{"id":229817,"date":"2026-01-26T13:07:13","date_gmt":"2026-01-26T19:07:13","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/easy-to-use-tool-can-identify-high-and-low-risk-metastatic-prostate-cancer-patients-earlier"},"modified":"2026-01-26T13:07:13","modified_gmt":"2026-01-26T19:07:13","slug":"easy-to-use-tool-can-identify-high-and-low-risk-metastatic-prostate-cancer-patients-earlier","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/easy-to-use-tool-can-identify-high-and-low-risk-metastatic-prostate-cancer-patients-earlier","title":{"rendered":"Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/easy-to-use-tool-can-identify-high-and-low-risk-metastatic-prostate-cancer-patients-earlier2.jpg\"><\/a><\/p>\n<p>A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.<\/p>\n<p>\u201cEarly decline in prostate-specific antigen (PSA) to very low levels is one of the strongest predictors of long-term survival in metastatic prostate cancer. However, clinicians currently have to wait up to six months after starting therapy to see whether a patient achieves this favorable response. For patients who do not respond well, this delay may allow the cancer to progress and become more resistant to treatment,\u201d said Soumyajit Roy, MD, a radiation oncologist at UH Seidman Cancer Center and first author of the study.<\/p>\n<p>Because existing clinical risk stratification tools\u2014such as disease volume or metastatic burden\u2014are relatively imprecise, there has been an unmet need for a reliable, easy-to-use tool that can risk stratify patients earlier, before that critical six-month window closes. Researchers wanted to determine whether it is possible to predict early treatment response at the time of diagnosis for men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with modern androgen receptor pathway inhibitors (ARPIs), which are now standard of care worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease. \u201cEarly decline in prostate-specific antigen (PSA) to very low levels is one of the strongest predictors of long-term survival in metastatic prostate cancer. However, clinicians currently have to wait [\u2026]<\/p>\n","protected":false},"author":707,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-229817","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/707"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=229817"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229817\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=229817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=229817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=229817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}